ES2308016T3 - Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc. - Google Patents

Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc. Download PDF

Info

Publication number
ES2308016T3
ES2308016T3 ES03791865T ES03791865T ES2308016T3 ES 2308016 T3 ES2308016 T3 ES 2308016T3 ES 03791865 T ES03791865 T ES 03791865T ES 03791865 T ES03791865 T ES 03791865T ES 2308016 T3 ES2308016 T3 ES 2308016T3
Authority
ES
Spain
Prior art keywords
alkyl
compound
aryl
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03791865T
Other languages
English (en)
Spanish (es)
Inventor
Wen-Lian Wu
Duane A. Burnett
William J. Greenlee
Thavalakulam K. Sasikumar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2308016T3 publication Critical patent/ES2308016T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES03791865T 2002-08-29 2003-08-27 Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc. Expired - Lifetime ES2308016T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40685602P 2002-08-29 2002-08-29
US406856P 2002-08-29

Publications (1)

Publication Number Publication Date
ES2308016T3 true ES2308016T3 (es) 2008-12-01

Family

ID=31978370

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03791865T Expired - Lifetime ES2308016T3 (es) 2002-08-29 2003-08-27 Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc.

Country Status (11)

Country Link
US (1) US7211574B2 (https=)
EP (1) EP1537115B1 (https=)
JP (1) JP4555685B2 (https=)
CN (1) CN1688584A (https=)
AT (1) ATE396996T1 (https=)
AU (1) AU2003262926A1 (https=)
CA (1) CA2495879C (https=)
DE (1) DE60321354D1 (https=)
ES (1) ES2308016T3 (https=)
MX (1) MXPA05002249A (https=)
WO (1) WO2004020442A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2526017A1 (en) * 2003-05-22 2005-04-21 Schering Corporation 5-h-benzo[d]naphth[2,1-b]azepine derivative as selective d1/d5 receptor antagonists for the treatment of obesity and cns disorders
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
KR900007781B1 (ko) * 1986-01-16 1990-10-20 쉐링 코포레이션 융합된 벤즈아제핀
ZA875183B (en) * 1987-07-15 1988-04-08 Schering Corporation Fused benzazepines
DK325188D0 (da) * 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
DE60206762T2 (de) * 2001-07-13 2006-07-13 Pharmacia & Upjohn Co. Llc, Kalamazoo Hexahydroazepino(4,5-g)indole und -indoline als 5-ht rezeptor-liganden

Also Published As

Publication number Publication date
JP4555685B2 (ja) 2010-10-06
US20040058906A1 (en) 2004-03-25
ATE396996T1 (de) 2008-06-15
AU2003262926A1 (en) 2004-03-19
CN1688584A (zh) 2005-10-26
CA2495879C (en) 2011-04-26
EP1537115B1 (en) 2008-05-28
MXPA05002249A (es) 2005-06-08
JP2006501244A (ja) 2006-01-12
EP1537115A1 (en) 2005-06-08
US7211574B2 (en) 2007-05-01
WO2004020442A1 (en) 2004-03-11
DE60321354D1 (de) 2008-07-10
CA2495879A1 (en) 2004-03-11

Similar Documents

Publication Publication Date Title
CN104825457B (zh) 用于治疗病症的方法和组合物
US11001564B2 (en) Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
ES2227287T3 (es) Compuestos quimicos.
JP4643141B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
ES2986581T3 (es) Antagonistas del receptor muscarínico de acetilcolina M4
JP7282082B2 (ja) 置換ピリミジンピペラジン化合物及びその使用
JP2006516640A (ja) 新規アリールピペラジニル化合物
ES2242856T3 (es) Antagonistas del ccr5 utiles para el tratamiento del sida.
WO2023115167A1 (en) Compounds
US10906896B2 (en) Compositions and methods for inhibiting kinases
BRPI0808707A2 (pt) Uso de derivados de benzimidazol e composição compreendendo os mesmos
BRPI0620386A2 (pt) composição compreendendo a combinação de um antagonista de h3/agonista inverso e um supressor de apetite e uso da referida composição
BR112012000413A2 (pt) compostos e composições para o tratamento de doenças parasitárias
US20190270733A1 (en) Quinoline and Isoquinoline Based HDAC Inhibitors and Methods of Use Thereof
WO2017030892A1 (en) Histone deacetylase inhibitors and methods for use thereof
WO2015169180A1 (en) Substituted piperazine compounds and methods and use thereof
WO2006088193A1 (ja) 抗腫瘍剤
US20090156830A1 (en) Substituted Imidazoline Compounds
EP4479399A1 (en) Adenosine ligands for the treatment of neurological disorders
ES2308016T3 (es) Anatagonistas selectivos de los receptores d1/d5 para el tratamiento de la obesidad y trastornos del snc.
ES2743701T3 (es) Conjugados de ligando-fármaco del receptor sigma-2 como compuestos antitumorales, métodos de síntesis y usos de los mismos
US10538491B2 (en) 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
US20250177382A1 (en) Nek7 inhibitors
US20040106629A1 (en) Compouds in the form of homodimeric, heterodimeric and/or homo and heteromultimeric pro-drugs; process for obtaining these pro-drugs and their acceptable pharmaceutical salts and use of compounds in the treatment of phosphodiesterasis-mediated deseases or dysfunction
JP2006501244A5 (https=)